Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

DRB18 is a pan-inhibitor of glucose transporters (Gluts).1 It inhibits glucose uptake in HEK293 cells expressing Glut1, Glut2, Glut3, or Glut4 (IC50s = 2.6, 8.8, 4.5, and 0.9 µM, respectively) and in A549 and H1299 non-small cell lung cancer (NSCLC) cells (IC50s = 2.5 and 1.9 µM, respectively). DRB18 (10 µM) decreases the oxygen consumption rate (OCR) in a time-dependent manner, induces cell cycle arrest at the G1/S phase, and increases the levels of reactive oxygen species (ROS) in A549 cells. It decreases tumor volume and weight in an A549 mouse xenograft model when administered at a dose of 10 mg/kg.
WARNING This product is not for human or veterinary use.
1. A small-